Description
This vial supplies CJC-1295 (No DAC) and Ipamorelin at 10mg each as a single lyophilized preparation, pairing a GHRH analog with a ghrelin receptor agonist.
The two act at different receptors. CJC-1295 without the Drug Affinity Complex — also described as modified GRF(1-29) — is a shortened GHRH sequence carrying amino acid substitutions that resist enzymatic degradation, and it acts at the GHRH receptor. Ipamorelin is a pentapeptide acting at GHSR-1a, the ghrelin receptor, studied for its selectivity relative to earlier secretagogues. Because the two inputs are independent, combination preparations exist specifically to examine additive or synergistic signaling in pituitary cell models.
What Is CJC-1295 (No DAC) + Ipamorelin?
CJC-1295 without DAC, also called Modified GRF (1–29), is based on the first 29 amino acids of growth hormone-releasing hormone, the shortest fully active portion of GHRH. It has four amino-acid substitutions that improve resistance to enzymatic breakdown. It has no drug affinity complex (DAC), so its half-life is short, similar to a natural GHRH pulse.
Ipamorelin is a pentapeptide agonist of the ghrelin receptor (GHS-R1a), a separate pathway that also triggers growth hormone release. Animal research has described Ipamorelin as notably selective, with little effect on ACTH or cortisol compared with earlier secretagogues. Researchers pair the two because GHRH-receptor and ghrelin-receptor signaling reach the pituitary through complementary mechanisms.
Areas of Research Interest
- GHRH-receptor and GHS-R1a (ghrelin receptor) co-signaling
- Pulsatile growth hormone release models
- IGF-1 axis response studies
- Secretagogue selectivity (ACTH / cortisol / prolactin)
- Comparative work with full-length GHRH analogs such as tesamorelin
Product Specifications
- Compound: CJC-1295 without DAC (Modified GRF 1–29) + Ipamorelin
- Contents: 10mg CJC-1295 (No DAC) / 10mg Ipamorelin per vial
- Form: Lyophilized powder
- Intended use: Laboratory research only
Handling & Storage
Supplied as a lyophilized (freeze-dried) powder in a sealed vial. Store according to the label, protected from heat, light and moisture.
Frequently Asked Questions
What does modified GRF(1-29) refer to?
It is another name for the CJC-1295 No DAC sequence — a shortened 29-amino-acid GHRH fragment carrying substitutions that resist enzymatic degradation. The two names appear interchangeably in published work, which is worth knowing when comparing sources.
Why combine a GHRH analog with a ghrelin receptor agonist?
They act on separate receptors with separate downstream signaling, so combining them lets researchers test whether the effects are additive, synergistic or independent — a question that cannot be examined with either compound alone.
What does No DAC mean?
DAC (drug affinity complex) is a chemical attachment that binds albumin and greatly extends half-life. The No DAC version, also called Modified GRF 1–29, leaves it off, so the peptide is short-acting.
Why combine CJC-1295 and Ipamorelin in one vial?
They act at two different receptors that both regulate growth hormone release, so labs studying combined signaling often use them together. For a full-length GHRH analog, see Tesamorelin.
Is CJC-1295 (No DAC) + Ipamorelin 10/10mg Vial intended for human use?
No. This product is sold strictly for in vitro and laboratory research by qualified professionals. It is not for human or veterinary use.
Related Research Compounds
Sold for research purposes only. Not intended for human consumption. These statements have not been evaluated by the FDA. This product is not a drug, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease.
Reviews
There are no reviews yet.